Neoprobe Corporation (NEOP) Recommended for $1 Million Lymphoseek Grant from Ohio Third Frontier  
6/24/2010 9:58:23 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative biomedical surgical oncology products, today announced that Ohio’s Third Frontier Commission has voted to award a grant of $1 million to fund ongoing development of Neoprobe’s Lymphoseek® radiopharmaceutical initiative, subject to the review of the State Controlling Board. The Ohio Third Frontier grant will be used to accelerate clinical testing for Neoprobe’s Phase 3 trial in patients diagnosed with head and neck squamous cell carcinoma. This trial is intended to expand the proposed product labeling for Lymphoseek following an initial broader product label. Neoprobe was among eight companies awarded Medical Imaging Program grants by the Commission.